|
|
Vaccine Detail
|
mRNA-1273.211 |
| Vaccine Information |
- Vaccine Name: mRNA-1273.211
- Target Pathogen: SARS-CoV-2
- Target Disease: COVID-19
- Manufacturer: Moderna
- Vaccine Ontology ID: VO_0005277
- Type: mRNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Immune Response: No cases of Covid-19 with an onset of 14 days after the second injection were reported in the mRNA-1273 group, and four cases occurred in the placebo group. (Ali et al., 2021)
- Side Effects: the most common solicited adverse reactions after the first or second injections were injection-site pain (in 93.1% and 92.4%, respectively), headache (in 44.6% and 70.2%, respectively), and fatigue (in 47.9% and 67.8%, respectively) (Ali et al., 2021)
- Efficacy: The mRNA-1273 vaccine had an acceptable safety profile in adolescents. (Ali et al., 2021)
|
| References |
Ali et al., 2021: Kashif Ali 1, Gary Berman 1, Honghong Zhou 1, Weiping Deng 1, Veronica Faughnan 1, Maria Coronado-Voges 1, Baoyu Ding 1, Jacqueline Dooley 1, Bethany Girard 1, William Hillebrand 1, Rolando Pajon 1, Jacqueline M Miller 1, Brett Leav 1, Roderick McPhee 1. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. . 2021; ; . [PubMed: 34379915].
|
|
